Phase 1B Study Evaluating Elranatamab in Combination with Carfilzomib/Dexamethasone or in Combination with PF-07901801 (maplirpacept) in Relapsed/Refractory Multiple Myeloma MAGNETISMM-20
Verified

What's the purpose of this trial?

The goal of this study is to evaluate the best dose, safety, and effectiveness of elranatamab when combined with carfilzomib and dexamethasone, and to evaluate the best dose, safety and effectiveness of PF-07901801 (maplirpacept)when combined with elranatamab in participants with relapsed/refractory multiple myeloma. 

This trial is currently open and accepting patients.

What will happen during the trial?

This clinical trial is organized into three different parts. This trial is open-label, which means that the participants and study team will know which part they are enrolled in, and which drugs/doses they will be receiving. Participants will be enrolled in only one part of the study, and will not be allowed to participate in other parts (rollover). 

In Part 1, researchers will evaluate the safety and best dose of elranatamab when combined with carfilzomib and dexamethasone. In Arm A of Part 2, researchers will evaluate the safety and best dose of PF-07901801 (maplirpacept) both by itself, and in combination with elranatamab. In Arm B of Part 2, researchers will give participants the doses of elranatamab and PF-07901801 (maplirpacept) determined to be safest and most effective by the previous groups.

The total length of this study can be 2 years or longer. You will continue to receive the study medicines until your multiple myeloma has progressed, you experience side effects that are hard to manage, or you choose to stop receiving the study medicines. You are free to stop being in the study at any time and for any reason; this will not affect your future medical care in any way.

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

  • have measurable disease as defined by the trial criteria
  • For Part 1 only:
    • have received 1-3 prior lines of therapy and have not received prior treatment with any anti-BCMA directed therapy 
    • prior treatment with carfilzomib is allowed as long as
      • you have had a partial response or better to therapy with carfilzomib,
      • you did not stop taking carfilzomib due to side effects,
      • your myeloma did not come back within 60 days of stopping carfilzomib,
      • and you have not had carfilzomib in the six months before joining this study
  • For Part 2 only:
    • should have received at least 3 lines of therapy and must be refractory to at least one immunomodulatory drug, proteasome inhibitor, and anti-CD38 antibody
    • may have been previously exposed to a BCMA CAR-T, as long as they achieved a partial response or better. No other BCMA exposure is allowed for participants in Part 2.
  • have not previously had treatment with a CD47-SIRP alpha directed therapy
  • have not had a stem cell transplant in the three months prior to enrollment

Additional Trial Information

Phase 1

Enrollment: 90 patients (estimated)

View More
Need Help?

Interested in joining or learning more about this trial?

(888) 828-2206

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.

Arkansas

University of Arkansas for Medical Sciences (UAMS)

Little Rock, AR

Open and Accepting

California

Beverly Hills Cancer Center

Beverly Hills, CA

Open and Accepting

Florida

Sylvester Comprehensive Cancer Center (Main) University of Miami Health System

Miami, FL

Open and Accepting

Georgia

Winship Cancer Institute Emory University

Atlanta, GA

Open and Accepting

Maryland

Sidney Kimmel Comprehensive Cancer Center Johns Hopkins Medicine

Baltimore, MD

Open and Accepting
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • Add this trial to your favorites keyboard_arrow_right

    If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message

SparkCures Verified

Learn more about how we work with trial sponsors